This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Plasma exchange has been evaluated for treatment of acute inflammatory demyelinating syndromes of the CNS, e.g., acute relapsing multiple sclerosis (MS).1–3 It was recently reported that the pathologic pattern type II4 predicts the response to plasmapheresis treatment.5 Notably, however, these investigators had studied patients with fulminant attacks of MS. In a commentary,6 these findings were put in the context of older studies on the utility of plasma exchange in MS.
Here, we report on a 32-year-old woman with a >6-year history of MS who had entered the chronic progressive phase 17 months before starting plasma exchange therapy. Prior to this, the patient had …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis
Default-mode network dysfunction and cognitive impairment in progressive MS
Familial effects on the clinical course of multiple sclerosis
Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency